SLN vs. SNDL, PRTC, UPB, RNAC, KMDA, TRDA, ETON, MREO, RVNC, and RAPP
Should you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include SNDL (SNDL), PureTech Health (PRTC), Upstream Bio (UPB), Cartesian Therapeutics (RNAC), Kamada (KMDA), Entrada Therapeutics (TRDA), Eton Pharmaceuticals (ETON), Mereo BioPharma Group (MREO), Revance Therapeutics (RVNC), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry.
Silence Therapeutics vs.
SNDL (NASDAQ:SNDL) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings, community ranking and analyst recommendations.
98.7% of Silence Therapeutics shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
SNDL currently has a consensus target price of $3.63, suggesting a potential upside of 150.00%. Silence Therapeutics has a consensus target price of $40.67, suggesting a potential upside of 1,082.17%. Given Silence Therapeutics' higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than SNDL.
Silence Therapeutics has lower revenue, but higher earnings than SNDL. SNDL is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Silence Therapeutics had 2 more articles in the media than SNDL. MarketBeat recorded 3 mentions for Silence Therapeutics and 1 mentions for SNDL. Silence Therapeutics' average media sentiment score of 1.08 beat SNDL's score of 0.02 indicating that Silence Therapeutics is being referred to more favorably in the news media.
SNDL received 98 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 79.63% of users gave Silence Therapeutics an outperform vote while only 71.94% of users gave SNDL an outperform vote.
SNDL has a net margin of -12.11% compared to Silence Therapeutics' net margin of -342.00%. SNDL's return on equity of -8.27% beat Silence Therapeutics' return on equity.
SNDL has a beta of 3.39, suggesting that its stock price is 239% more volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
Summary
Silence Therapeutics beats SNDL on 10 of the 18 factors compared between the two stocks.
Get Silence Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silence Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SLN) was last updated on 3/31/2025 by MarketBeat.com Staff
